Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer

Figures & data

Table 1. Patient and tumor characteristics of patients with solitary and synchronous primary NSCLC treated with SBRT.

Patient Characteristics	Synchronous Primary (n = 36)	Solitary Primary (n = 272)	Overall (n = 308)	p
Age (median [IQR])	73 [67, 77]	71 [65, 79]	72 [65, 78]	.84
Gender (%)
Female	22 (61.1)	94 (34.6)	116 (37.7)	<.01
Male	14 (38.9)	178 (65.4)	192 (62.3)
BMI (median [IQR])	25.00 [22.15, 27.60]	25.27 [22.20, 30.58]	25.23 [22.20, 30.50]	.6
ECOG (%)
0	1 (2.9)	18 (6.6)	19 (6.2)	.64
1	21 (61.8)	132 (48.5)	153 (50.0)
2	10 (29.4)	96 (35.3)	106 (34.6)
3	2 (5.9)	25 (9.2)	27 (8.8)
4	0 (0.0)	1 (0.4)	1 (0.3)
Smoking status (%)
Never	2 (5.9)	10 (3.7)	12 (3.9)	.3
Current	15 (44.1)	89 (32.7)	104 (34.0)
Former	17 (50.0)	173 (63.6)	190 (62.1)
Pulmonary function test (%)
No	12 (35.3)	141 (51.8)	153 (50.0)	.1
Yes	22 (64.7)	131 (48.2)	153 (50.0)
Supplemental oxygen (%)
No	29 (85.3)	220 (81.2)	249 (81.6)	.73
Yes	5 (14.7)	51 (18.8)	56 (18.4)
PET/CT (%)
No	0 (0.0)	15 (5.5)	15 (4.9)	.31
Yes	35 (100.0)	257 (94.5)	292 (95.1)
MRI brain (%)
No	17 (48.6)	209 (76.8)	226 (73.6)	<.01
Yes	18 (51.4)	63 (23.2)	81 (26.4)
Biopsy (%)
No	4 (11.1)	77 (28.3)	81 (26.3)	.05
Yes	32 (88.9)	195 (71.7)	227 (73.7)
Tumor Characteristics	Synchronous Primary (n = 73)	Solitary Primary (n = 272)	Overall (n = 345)	p
Central lesion (%)
No	60 (82.2)	238 (87.5)	298 (86.4)	.33
Yes	13 (17.8)	34 (12.5)	47 (13.6)
Peripheral lesion (%)
No	22 (30.1)	70 (25.7)	92 (26.7)	.54
Yes	51 (69.9)	202 (74.3)	253 (73.3)
Lesion biopsied (%)
No	34 (46.6)	77 (28.3)	111 (32.2)	<.01
Yes	39 (53.4)	195 (71.7)	234 (67.8)
Histology of biopsied lesion (%)
Adenocarcinoma	20 (51.3)	85 (43.8)	105 (45.1)	.49
Squamous cell carcinoma	16 (41.0)	80 (41.2)	96 (41.2)
Adenosquamous	1 (2.6)	1 (0.5)	2 (0.9)
Large cell	0 (0.0)	3 (1.5)	3 (1.3)
NSCLC NOS	2 (5.1)	22 (11.3)	24 (10.3)
Other	0 (0.0)	3 (1.5)	3 (1.3)
T stage (AJCC 8^th ed.) (%)^a
T1a	16 (21.9)	23 (8.5)	39 (11.3)	.01
T1b	35 (47.9)	123 (45.2)	158 (45.8)
T1c	18 (24.7)	92 (33.8)	110 (31.9)
T2a	3 (4.1)	26 (9.6)	29 (8.4)
T2b	1 (1.4)	8 (2.9)	9 (2.6)
Stage (AJCC 8^th ed.) (%)^a
IA	69 (94.5)	238 (87.5)	307 (89.0)	.23
IB	3 (4.1)	26 (9.6)	29 (8.4)
IIA	1 (1.4)	8 (2.9)	9 (2.6)
Tumor size (median [range])	1.50 [0.6, 4.2]	1.95 [0.7, 5.0]	1.90 [0.6, 5.0]	<.01
Dose (median [range])	50.0 [50.0, 60.0]	50.0 [34.0, 54.0]	50.0 [34.0, 60.0]	.74
BED10 (median [range])	100.0 [75.0, 151.20]	100.0 [75.0, 151.2]	100.0 [75.0, 151.2]	.39

ECOG: Eastern Cooperative Oncology Group performance status; EBUS: endobronchial ultrasound; BED: biologically effective dose.

^aLesions were individually staged using T-stage based on size as each individual lesion was defined as a primary rather than a satellite nodule (T3/4).

Patients with missing data for the particular variable of interest are excluded.

Figure 1. Progression-free survival (A) and overall survival (B) for patients treated with SBRT to synchronous early-stage NSCLC.

Figure 2. Cumulative incidence of local failure (A) and regional/distant failure (B) with death as a competing risk for patients treated with SBRT to synchronous early-stage NSCLC. Solid line: failure; Dashed line: death without failure.

Figure 3. Progression-free survival (A) and overall survival (B) after SBRT to a solitary early stage NSCLC versus synchronous primary NSCLC.